TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31952131
Drug: Three dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dates daily for 16 weeks
Study: 27142792
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg + Ezetimibe 10 mg
Study: 12056673
Drug: Cinnarizine 15
Normalized name: cinnarizine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 15 mg
Study: 12056673
Drug: Cinnarizine 30
Normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 30 mg
Study: 12056673
Drug: Cinnarizine 45
Normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine 45 mg
Study: 12056673
Drug: Promethazine 10
Normalized name: promethazine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 10 mg (active control)
Study: 6461679
Drug: Isotretinoin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin (1 mg/kg)
Study: 6461679
Drug: Etretinate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etretinate (1 mg/kg)
Study: 9066317
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (10 micrograms) plus bupivacaine (2.5 mg) plus epinephrine (0.2 mg)
Study: 9066317
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil (10 micrograms) plus bupivacaine (2.5 mg) plus normal saline (control)
Study: 20433999
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin nadroparin
Study: 19229379
Drug: Oral ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoprofen (300 mg)
Study: 19229379
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (4 g)
Study: 1832372
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (2 mg)
Study: 1832372
Drug: Aerosol pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol pentamidine (60 mg)
Study: 463806
Drug: Natural orange
Normalized name: Dex4 Natural Orange
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural orange juice (80 mg of ascorbic acid daily)
Study: 463806
Drug: Synthetic orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic orange juice (80 mg of ascorbic acid daily)
Study: 23450052
Drug: PCOS women
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCOS women with lower insulin sensitivity index (Si)
Study: 16642421
Drug: Protected alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protected alendronate 70 mg/day
Study: 16642421
Drug: Standard alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard alendronate 70 mg/day
Study: 10073783
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day of quinapril
Study: 6160322
Drug: Metoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (10 mg IV)
Study: 6160322
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg IV)
Study: 18797697
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg a day, orally)
Study: 15736995
Drug: Nine-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-valent pneumococcal conjugate vaccine
Study: 12432338
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day tamoxifen (n=16)
Study: 12432338
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day tamoxifen (n=16)
Study: 12432338
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day tamoxifen (n=15)
Study: 10525131
Drug: LDL-apheresis (LA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis (LA) combined with simvastatin 40 mg per day
Study: 8624230
Drug: Oscillating/rotating brush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oscillating/rotating brush (Braun Oral‐B Plaque Remover)
Study: 7400475
Drug: Oral theophylline
Normalized name: theophylline Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral theophylline solution
Study: 7400475
Drug: Rectal theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal theophylline solution
Study: 30088266
Drug: i-gel™ laryngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel™ laryngeal mask
Study: 23506128
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 mcg every 4 hours)
Study: 31640452
Drug: Office-based vergence/accommodative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Office-based vergence/accommodative therapy (OBVAT)
Study: 17902524
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (50 micrograms every 4-6 hours, max six doses)
Study: 17902524
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (50 micrograms every 4-6 hours, max six doses)
Study: 9235216
Drug: Combined phenibut
Normalized name: phenibut
DrugBank: Phenibut (DB13455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined phenibut (0.25 g) with obsidan (0.08 g)
Study: 9235216
Drug: Bemethyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bemethyl (0.5 g)
Study: 9235216
Drug: Obsidian (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obsidian (0.08 g)
Study: 8444102
Drug: Halofantrin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrin (three doses of 500 mg)
Study: 8444102
Drug: Halofantrin (one-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrin (one-day therapy)
Study: 3028964
Drug: Non-absorbable antimicrobial
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-absorbable antimicrobial drugs (polymyxin and neomycin)
Study: 31164006
Drug: Treatment-resistant schizophrenia
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-resistant schizophrenia
Study: 27580103
Drug: Tilmicosin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilmicosin (20 mg/kg, SC) once at dry off
Study: 27580103
Drug: Tilmicosin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilmicosin (20 mg/kg, SC) twice (once at dry off and again 20 days later)
Study: 27580103
Drug: Ceftiofur (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftiofur (500 mg/mammary gland) at dry off
Study: 21279932
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Atorvastatin daily for 6 months
Study: 21279932
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Atorvastatin daily for 6 months
Study: 21279932
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Atorvastatin daily for 6 months
Study: 21279932
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin therapy
Study: 18359821
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (GTN) therapy with physical therapy
Study: 18359821
Drug: Standard nonoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nonoperative physical therapy
Study: 18359821
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (GTN) therapy
Study: 18359821
Drug: Standard nonoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nonoperative therapy
Study: 16238586
Drug: Dpt specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dpt specific immunotherapy (IT)
Study: 12030918
Drug: GHRP-2 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRP-2 + TRH + GnRH infusion
Study: 12030918
Drug: GHRP-2 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRP-2 + TRH infusion
Study: 10720964
Drug: High-fiber diet
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fiber diet (> 25 g/day)
Study: 18476119
Drug: Butoconazole nitrate
Normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butoconazole nitrate 2% cream for 3 days
Study: 18476119
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate 2% cream for 7 days
Study: 1593018
Drug: Human alpha
Normalized name: Human alphaherpesvirus 1 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human alpha leukocyte interferon (IFN) 50,000 IU, 1 ml, twice a week for 4-6 weeks
Study: 1593018
Drug: Human alpha
Normalized name: Human alphaherpesvirus 1 Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human alpha leukocyte interferon (IFN) 50,000 IU, 1 ml, twice a week for 4-6 weeks + IL-2
Study: 4041688
Drug: Family management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family management based on behavioural family therapy
Study: 28538111
Drug: Antisense oligonucleotide
Normalized name: Antisense oligonucleotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisense oligonucleotide targeting ANGPTL3 mRNA (single dose: 20, 40, or 80 mg; multiple doses: 10, 20, 40, or 60 mg per week for 6 weeks)
Study: 25320185
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 0.2 to 2.0 g · kg(‐1) · d(‐1)
Study: 20729765
Drug: Isoflavones (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (80 mg daily for 4 months)
Study: 19482863
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon beta-1a (IFNbeta-1a) 30 mug once weekly
Study: 16549833
Drug: COL-3 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-3 (50 mg/d)
Study: 16549833
Drug: COL-3 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-3 (100 mg/d)
Study: 16549833
Drug: COL-3 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: COL-3 (50 mg/d and 100 mg/d)
Study: 12637625
Drug: Enfuvirtide plus
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enfuvirtide plus an optimized background regimen of three to five antiretroviral drugs
Study: 9232087
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone 200 micrograms/q.i.d.
Study: 9232087
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 200 micrograms/q.i.d.
Study: 9232087
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not requiring steroids)
Study: 26023227
Drug: l-Citrulline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Citrulline (6 g/day)
Study: 26023227
Drug: l-Arginine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-Arginine (6 g/day)
Study: 23473847
Drug: Three-drug ART
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug ART (NNRTI, lamivudine, abacavir)
Study: 23473847
Drug: Four-drug ART
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug ART (NNRTI, lamivudine, abacavir, zidovudine)
Study: 22036246
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 50/50 (TID group)
Study: 22036246
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mix 75/25 or biphasic insulin aspart 70/30 (BID group)
Study: 15670201
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily (n = 12)
Study: 15670201
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg twice weekly (n = 11)
Study: 15670201
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily (n = 14)
Study: 9480230
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin treatment without Camit-Diacomp system
Study: 8173753
Drug: Inhaled PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inhaled PGE2
Study: 29618162
Drug: Tinzaparin (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (175 IU/kg once daily)
Study: 26805417
Drug: Formulation containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation containing 4‐t‐butylcyclohexanol
Study: 26805417
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base containing 4‐t‐butylcyclohexanol and licochalcone A
Study: 23128469
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (2,000 IU once daily for 12 weeks)
Study: 20795425
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL fish oil daily (550 mg eicosapentaenoic acid; 205 mg decosahexaenoic acid)
Study: 20795425
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL fish oil daily
Study: 12826985
Drug: bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion (150 mg) once daily
Study: 12826985
Drug: bupropion (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupropion (300 mg)
Study: 12826985
Drug: methylphenidate SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate SR (20 mg daily)
Study: 11256129
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia using Propofol/Sufentanil (TIVA)
Study: 9006528
Drug: 7‐mg/kg cefdinir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐mg/kg cefdinir, twice daily, for 5 days
Study: 9006528
Drug: 10‐mg/kg penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg/kg penicillin V potassium, 4 times daily, for 10 days
Study: 8314358
Drug: cilazapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilazapril (5 mg o.d.)
Study: 8314358
Drug: atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (100 mg o.d.)
Study: 23204220
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol 2000 IU/day
Study: 21543930
Drug: Time from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time from primary treatment to recurrence
Study: 17715049
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target controlled infusion (TCI)
Study: 15549974
Drug: Diprivan mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprivan mixed with lidocaine 10 mg
Study: 11911312
Drug: 5-FU intravenous
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU intravenous injection at 1000 mg/m2 body surface area/24 hours for 72 hours + oral HCFU 300 mg daily for 52 weeks (Group B)
Study: 11911312
Drug: 5-FU intravenous
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU intravenous injection at 333 mg/m2 body surface area/24 hours for 72 hours + oral HCFU 300 mg daily for 52 weeks (Group A)
Study: 2493100
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment base
Study: 28853303
Drug: DASHNa‐CC intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASHNa‐CC intervention (Dietary Approach to Stop Hypertension With Sodium Reduction for Chinese Canadian)
Study: 28853303
Drug: DASHNa‐CC intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: DASHNa‐CC intervention
Study: 23562009
Drug: Daclizumab HYP
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab HYP 150 mg
Study: 23562009
Drug: Daclizumab HYP
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab HYP 300 mg
Study: 21796092
Drug: PEVAR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEVAR with adjunctive 'pre-close' techniques using ProGlide or Prostar XL devices
Study: 19921354
Drug: Landiolol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Landiolol infusion (0.125 mg kg(‐1) min(‐1) for 1 min, then 0.04 mg kg(‐1) min(‐1) until extubation)
Study: 16963585
Drug: Pharmacologic antidepressant
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic antidepressant treatment
Study: 15673949
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg/day for 3 weeks
Study: 15673949
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg/day for 3 weeks
Study: 2265331
Drug: Intravenous Avafortan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Avafortan
Study: 2265331
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of prostaglandin synthetase inhibitors
Study: 26341820
Drug: Brief support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief support (monthly weigh-ins and meeting)
Study: 26341820
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing (with brief monthly feedback)
Study: 20430112
Drug: Rate-controlling medications
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rate-controlling medications
Study: 15714841
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medication with methylphenidate plus consultation)
Study: 10405869
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a year deworming with single dose mebendazole
Study: 19700413
Drug: Cryotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy and podophyllotoxin 0.15% cream
Study: 17933157
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of risperidone
Study: 15292666
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract LI160 (300 mg twice a day for 2 weeks)
Study: 8262685
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal therapeutic system (TTS)
Study: 8262685
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal therapeutic system (TTS)
Study: 3898725
Drug: Citalopram (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-80 mg, most frequently 40 mg)
Study: 3898725
Drug: Mianserin (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (60-120 mg, most frequently 90 mg)
Study: 29283682
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula oxygen therapy plus long-term oxygen therapy
Study: 29283682
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy only
Study: 23412098
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + 400 mg upamostat (arm C)
Study: 23412098
Drug: Gemcitabine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine + 200 mg upamostat (arm B)
Study: 16641530
Drug: Epidural continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural continuous infusion without an initial dose (continuous group)
Study: 16641530
Drug: Epidural continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural continuous infusion with an initial dose (initial dose group)
Study: 11050836
Drug: Cefuroxime 750
Normalized name: cefuroxime 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 750 mg t.i.d, i.v.
Study: 11050836
Drug: Cephradine 1
Normalized name: cephradine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine 1 g q.i.d., i.v.
Study: 8617907
Drug: Exercise for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise for 60 minutes twice a week for 6 months
Study: 22143257
Drug: Daily educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily educational text messages for 180 days
Study: 21695161
Drug: Praziquantel 60
Normalized name: praziquantel 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 60 mg/kg
Study: 20549040
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 4 mg triamcinolone acetonide
Study: 14993078
Drug: Chizukit (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chizukit (herbal preparation containing 50 mg/mL of echinacea, 50 mg/mL of propolis, and 10 mg/mL of vitamin C)
Study: 9088587
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg day‐1 for 14 days)
Study: 30234415
Drug: Clovinol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clovinol (250 mg per day)
Study: 27396951
Drug: Bevacizumab (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (alone or in combination with CCNU)
Study: 25072529
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CRFD treatment followed by supplementary application)